No. Stentra™ is fabricated from low-density, non-metallic materials that are radiographically visible on CT but do not attenuate or scatter the therapeutic radiation beam. It integrates seamlessly into standard treatment planning workflows and does not require dose modification or beam compensation, preserving planning accuracy and clinical efficiency.

Yes. Stentra™ is eligible for reimbursement using current CPT codes for radiation therapy immobilization devices—typically CPT 77334 for custom, complex devices. Reimbursement amounts will vary based on payer policies, correct code selection, and supporting documentation. We supply clients with onboarding tools including coding guidance and claim-ready documentation templates to optimize codability and reimbursement.

Stentra™ devices are manufactured using a high-resolution additive manufacturing process (3D printing) with a biocompatible, medical-grade resin. This approach ensures clinical precision, consistent reproducibility, and a smooth surface finish—critical for intraoral comfort, safety, and anatomical conformity.

No. Stentra™ is fabricated from low-density, non-metallic materials that are radiographically visible on CT but do not attenuate or scatter the therapeutic radiation beam. It integrates seamlessly into standard treatment planning workflows and does not require dose modification or beam compensation, preserving planning accuracy and clinical efficiency.

Kallisio is a medical innovation company focused on improving the quality of care in treatments through technological precision advancements. Our mission is to enhance precision, comfort, and outcomes for patients.

Oncology is our first area of focus, starting with head and neck cancer. But our technology is designed to scale across multiple specialties where patient-specific solutions can improve treatment outcomes.

Kallisio’s mission to deliver precision therapeutic devices directly translates into better patient care by enabling clinicians to provide highly targeted, anatomically accurate, and patient-specific support during treatment. Our digital platform combines clinical insight, design automation, and rapid 3D manufacturing to produce personalized devices—like Stentra™—that improve treatment precision, and enhance patient comfort and adherence. This integration of technology and care helps minimize delays, optimize clinical outcomes, and support a more compassionate, effective treatment experience from day one.

Kallisio’s Stentra™ platform stands apart by offering true personalization through millimeter-accurate, 3D-printed devices designed from each patient’s unique anatomy and treatment plan. Unlike prefabricated or semi-custom tools, Stentra™ not only immobilizes but also displaces critical structures such as the tongue, optimizes oral aperture, and enhances radiation delivery precision. Our simulation-ready devices are delivered within 72 hours, require no additional software, integrate seamlessly into existing workflows, and are CPT-reimbursable—enabling scalable, high-precision care without disrupting clinical operations.

Yes. The Kallisio Clinical Portal is fully HIPAA-compliant. It is designed to neither collect, store, nor transmit Protected Health Information. Each case is managed using a system-generated unique device identifier, ensuring patient confidentiality while maintaining institutional control and traceability.

Stentra™ is designed for patients undergoing radiation therapy for head and neck cancers. It is particularly beneficial for those who need precise tongue and jaw positioning during treatment, including individuals with complex anatomies or without natural teeth (edentulous). Each device is customized to the patient’s unique anatomy to help improve the accuracy of radiation delivery and reduce exposure to healthy tissues. Ask your doctor if Stentra™ may be appropriate for your treatment plan.

Stentra™ is based on clinical research showing that customized oral stents can improve the precision of radiation delivery, reduce exposure to healthy tissues, and lessen treatment-related side effects. Studies also highlight improvements in patient comfort and treatment compliance, especially for those undergoing head and neck radiation therapy. Talk to your doctor about how Stentra™ may support your care.

After your oral scan is submitted, your custom Stentra™ stent is designed, 3D printed and delivered within 72 hours. It’s typically ready before your first radiation treatment session, ensuring there’s no delay in your care.

Yes. We work with international partners and can adapt shipping and support services to meet regional requirements. Please contact us to confirm availability and service options in your country.

The program offers your team direct experience with Stentra™—Kallisio’s FDA-cleared, patient-specific oral stent for head and neck radiation therapy. It enables evaluation of clinical benefits such as improved patient positioning, potential reduction in oral mucositis, and enhanced treatment tolerance. Additionally, your team can assess workflow integration, billing feasibility using existing CPT codes, and potential long-term return on investment.

Select up to 10 head and neck cancer patients and assign a team member to upload cases via Kallisio’s secure clinical portal. An intraoral scanner is preferred—Kallisio can assist if one is not available. Device fit is verified during CT simulation. Follow-up is required to share toxicity and setup reproducibility data, which are essential to assessing clinical and operational impact.